SV2A and epilepsy: Traditionally, this protein has been associated with epilepsy for three main reasons: (1) SV2A is the molecular target of the antiepileptic drug levetiracetam, (2) SV2A knockout mice suffer from seizures from postnatal day 7 and die 2 weeks later, and (3) the brain expression of SV2A in animal models and patients with epilepsy is lower than in healthy controls (Crowder et al., 1999; Lynch et al., 2004; Klitgaard and Verdru, 2007; van Vliet et al., 2009; Sills, 2010).